
GNMSF
Healthcare · Biotechnology · $31.42B market cap
$509.500.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 6, 2026 | After the close | 23.61 | 4.91 | -79.2% |
| May 7, 2026 | After the close | 9.21 | 0.83 | -91.0% |
| Feb 17, 2026 | After the close | 29.33 | 0.46 | -98.4% |
| Nov 6, 2025 | After the close | 31.81 | 6.46 | -79.7% |
| Aug 7, 2025 | After the close | 25.72 | 5.46 | -78.8% |
| Apr 30, 2025 | After the close | — | 3.05 | — |
| Feb 12, 2025 | After the close | — | 8.60 | — |
| Nov 6, 2024 | After the close | 3.24 | 2.85 | -12.0% |
| Aug 8, 2024 | After the close | 20.48 | 21.70 | +6.0% |
| May 2, 2024 | After the close | 12.23 | 20.18 | +65.0% |
| Feb 14, 2024 | After the close | 23.06 | 9.67 | -58.1% |
| Nov 7, 2023 | After the close | 20.69 | 32.32 | +56.2% |
| Aug 3, 2023 | After the close | 19.15 | 20.61 |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with…
| +7.6% |
| May 10, 2023 | After the close | 4.43 | 3.43 | -22.6% |
| Feb 22, 2023 | After the close | 27.55 | 8.77 | -68.2% |
| Nov 9, 2022 | After the close | 19.20 | 39.17 | +104.0% |
| Aug 10, 2022 | After the close | 15.30 | 28.66 | +87.3% |
| May 11, 2022 | After the close | — | 7.05 | — |
| Feb 16, 2022 | After the close | 9.90 | 10.82 | +9.3% |
| Nov 10, 2021 | After the close | 8.30 | 13.47 | +62.3% |
| Aug 11, 2021 | After the close | 4.20 | 4.64 | +10.5% |
| May 5, 2021 | After the close | 4.03 | 16.61 | +312.2% |
| Feb 23, 2021 | After the close | 8.00 | 8.75 | +9.4% |
| Nov 4, 2020 | After the close | — | 8.04 | — |
| Aug 12, 2020 | After the close | — | 51.35 | — |
| May 6, 2020 | After the close | 0.00 | 4.09 | — |
| Feb 19, 2020 | After the close | 24.80 | 23.00 | -7.3% |
| Nov 6, 2019 | After the close | 3.76 | 8.28 | +120.2% |
| Aug 14, 2019 | After the close | 1.58 | 1.35 | -14.6% |
| May 8, 2019 | After the close | 1.41 | 1.17 | -17.0% |
| Feb 20, 2019 | After the close | 8.58 | 13.44 | +56.6% |
| Nov 14, 2018 | After the close | 3.60 | 2.89 | -19.7% |
| Aug 8, 2018 | After the close | 2.46 | 4.21 | +71.1% |
| May 8, 2018 | After the close | 5.60 | 3.20 | -42.9% |
| Feb 21, 2018 | After the close | 8.04 | 12.65 | +57.3% |